- Celgosivir
-
- $357.00 / 10mg
-
2025-10-27
- CAS:121104-96-9
- Min. Order:
- Purity: 98.03%
- Supply Ability: 10g
- Celgosivir
-
- $357.00 / 10mg
-
2025-10-20
- CAS:121104-96-9
- Min. Order:
- Purity: 98.03%
- Supply Ability: 10g
- celgosivir
-
- $1.00 / 1g
-
2020-02-02
- CAS:121104-96-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200g
|
| | celgosivir Basic information |
| Product Name: | celgosivir | | Synonyms: | celgosivir;MDL 28574;(1S)-1,2,3,5,6,7,8,8aα-Octahydro-6α-butyryloxyindolizine-1β,7β,8α-triol;6-Butyryl castanospermine;Castanospermine 6-butyrate;BuCast;MDL28574;MDL-28574;MDL 28574;MBI 3253 | | CAS: | 121104-96-9 | | MF: | C12H21NO5 | | MW: | 259.3 | | EINECS: | | | Product Categories: | | | Mol File: | 121104-96-9.mol |  |
| | celgosivir Chemical Properties |
| Melting point | 114-115 °C | | Boiling point | 422.9±45.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | Chloroform (Slightly), DMSO (Slightly) | | form | Solid | | pka | 13.14±0.70(Predicted) | | color | White to Pale Beige | | Water Solubility | H2O: 2mg/mL, clear | | Stability: | Hygroscopic |
| | celgosivir Usage And Synthesis |
| Uses | Antiviral; inhibitor ( α-glucosidase). | | Uses | Celgosivir is an α-glucosidase I inhibitor. | | Biological Activity | Celgosivir is a prodrug of natural bicyclic iminosugar castanospermine th at exhibits antiviral activity in vivo including HCV and dengue. Celgosivir is an inhibitor of α-glucosidases, which inhibits glycoprotein processing in cell culture. Apparently inhibition of α-glucosidases within infected cell prevents secretion of virus. | | in vivo | Celgosivir fully protects AG129 mice from lethal infection with a mouse adapted dengue virus at a dose of 50 mg/kg twice daily (BID) for 5 days and is effective even after 48 h delayed treatment. The protection by celgosivir is dose- and schedule-dependent and that a twice-a-day regimen of 50, 25 or 10 mg/kg is more protective than a single daily dose of 100 mg/kg. Pharmacokinetics studies of celgosivir in mice shows that it rapidly metabolizes to castanospermine[4]. During primary infection with a mouse-adapted DENV strain S221, mice shows increased viremia on day 3, yet 80% survived day 10 with virus completely cleared by day 8[3]. | | IC 50 | HIV-1 |
| | celgosivir Preparation Products And Raw materials |
|